scholarly journals Cancer Treatment–Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer

2018 ◽  
Vol 2 (7) ◽  
pp. 574-588 ◽  
Author(s):  
Pamela Taxel ◽  
Erika Faircloth ◽  
Sana Idrees ◽  
Catherine Van Poznak
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Bone Loss ◽  
Cancer Treatment

scholarly journals Pharmacotherapy Options in Cancer Treatment-induced Bone Loss: Focus on Bisphosphonates

2009 ◽  
Vol 1 ◽  
pp. CMT.S2064
Author(s):  
Kouta Ito
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Bone Loss ◽  
Cancer Survivors ◽  
Cancer Treatment ◽  
Small Sample ◽  
Ablation Therapy ◽  
Prostate Cancer Survivors ◽  
Hormone Ablation ◽  
Hormone Ablation Therapy

Bone loss and its associated risk of fracture is a serious long-term health issue for breast cancer and prostate cancer survivors. Hormone ablation therapy, in particular aromatase inhibitors (AIs) for breast cancer and androgen deprivation therapy (ADT) for prostate cancer, causes marked reduction in circulating estrogen or testosterone levels, resulting in increased bone resorption, decreased bone mineral density (BMD), and an increased risk of fragility fracture. In several clinical trials with small sample sizes and short follow-up periods, oral and intravenous bisphosphonates have been shown to improve BMD, but not actual fracture rates, in cancer patients on hormone ablation therapy. A number of professional organizations and expert panels recommend the use of bisphosphonates for selected patients at risk. Although bisphosphonates are generally well tolerated, physicians should be aware of safety concerns, including the risk of osteonecrosis of the jaw. With the growing number of older breast and prostate cancer survivors, additional research is needed to characterize patients who would benefit from pharmacotherapy and optimize strategies to prevent cancer treatment-induced bone loss.

scholarly journals Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy

2021 ◽  
Vol 22 (5) ◽  
Author(s):  
Anna Diana ◽  
Francesca Carlino ◽  
Emilio Francesco Giunta ◽  
Elisena Franzese ◽  
Luigi Pio Guerrera ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Loss ◽  
Cancer Treatment ◽  
Endocrine Therapy ◽  
Aromatase Inhibitors ◽  
Bone Health ◽  
Optimal Time ◽  
Breast Cancer Patients ◽  
Antiresorptive Agents

Opinion statementAbout 70–80% of early breast cancer (BC) patients receive adjuvant endocrine therapy (ET) for at least 5 years. ET includes in the majority of cases the use of aromatase inhibitors, as upfront or switch strategy, that lead to impaired bone health. Given the high incidence and also the high prevalence of BC, cancer treatment–induced bone loss (CTIBL) represents the most common long-term adverse event experimented by patients with hormone receptor positive tumours. CTIBL is responsible for osteoporosis occurrence and, as a consequence, fragility fractures that may negatively affect quality of life and survival expectancy. As recommended by main international guidelines, BC women on aromatase inhibitors should be carefully assessed for their fracture risk at baseline and periodically reassessed during adjuvant ET in order to early detect significant worsening in terms of bone health. Antiresorptive agents, together with adequate intake of calcium and vitamin D, should be administered in BC patients during all course of ET, especially in those at high risk of osteoporotic fractures, as calculated by tools available for clinicians. Bisphosphonates, such as zoledronate or pamidronate, and anti-RANKL antibody, denosumab, are the two classes of antiresorptive drugs used in clinical practice with similar efficacy in preventing bone loss induced by aromatase inhibitor therapy. The choice between them, in the absence of direct comparison, should be based on patients’ preference and compliance; the different safety profile is mainly related to the route of administration, although both types of drugs are manageable with due care, since most of the adverse events are predictable and preventable. Despite advances in management of CTIBL, several issues such as the optimal time of starting antiresorptive agents and the duration of treatment remain unanswered. Future clinical trials as well as increased awareness of bone health are needed to improve prevention, assessment and treatment of CTIBL in these long-term survivor patients.

ONS Guidelines™ for Cancer Treatment–Related Hot Flashes in Women With Breast Cancer and Men With Prostate Cancer

2020 ◽  
Vol 47 (4) ◽  
pp. 374-399
Author(s):  
Marcelle Kaplan ◽  
Pamela Ginex ◽  
Laura Michaud ◽  
Paz Fernández-Ortega ◽  
Dale Grimmer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Cancer Treatment ◽  
Hot Flashes

scholarly journals 131. MANAGMENT OF BREAST CANCER TREATMENT–INDUCED BONE LOSS

Rheumatology ◽  
2017 ◽  
Vol 56 (suppl_2) ◽  
Author(s):  
Shyanthi Pattapola ◽  
Anupama Nandagudi
Keyword(s):  
Breast Cancer ◽  
Bone Loss ◽  
Cancer Treatment ◽  
Breast Cancer Treatment

scholarly journals Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group

2020 ◽  
Vol 25 ◽  
pp. 100311
Author(s):  
Janet E. Brown ◽  
Catherine Handforth ◽  
Juliet E. Compston ◽  
William Cross ◽  
Nigel Parr ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Loss ◽  
Cancer Treatment ◽  
Position Statement ◽  
Expert Group ◽  
Prostate Cancer Treatment
Sign in / Sign up

Export Citation Format

Share Document